Meropenem Coverage of Enterococcus faecalis
No, meropenem does NOT provide reliable coverage against Enterococcus faecalis and should not be used as monotherapy for this organism.
FDA-Approved Indication
According to the FDA label, meropenem is indicated for complicated skin and skin structure infections caused by Enterococcus faecalis (vancomycin-susceptible isolates only) 1. However, this indication is misleading in clinical practice, as the drug's activity against enterococci is limited and unreliable.
Guideline Recommendations
The 2010 Surgical Infection Society/IDSA guidelines explicitly state that antibiotics that can potentially be used against E. faecalis include ampicillin, piperacillin-tazobactam, and vancomycin 2. Notably, meropenem is NOT listed among the recommended anti-enterococcal agents. When these guidelines recommend carbapenems (including meropenem) for healthcare-associated intra-abdominal infections, they specifically note that additional anti-enterococcal coverage should be added when enterococci are suspected 2.
The 2024 WHO guidelines similarly recommend ampicillin as the primary agent for enterococcal coverage in intra-abdominal infections, with no mention of meropenem for this purpose 3.
Microbiologic Reality
Limited Activity
- Meropenem demonstrates only moderate activity against E. faecalis with MIC₉₀ values of 8 mg/L 4
- Comparative studies show meropenem has less activity against gram-positive organisms, particularly enterococci, compared to imipenem 5, 6
- Recent susceptibility data shows only 73.9% sensitivity of Enterococcus species to meropenem 7
Combination Therapy Shows Promise
- Recent in vitro data (2022) demonstrates that meropenem plus ceftaroline achieves significant kill against E. faecalis, comparable to the standard ampicillin plus ceftriaxone regimen 8
- Meropenem combined with teicoplanin shows 40% synergy against E. faecalis 4
- However, these are experimental combinations not yet validated in clinical practice
Clinical Algorithm
When E. faecalis coverage is needed:
First-line agents:
- Ampicillin (preferred)
- Piperacillin-tazobactam
- Vancomycin (if ampicillin-resistant or penicillin allergy)
If already on meropenem for other indications:
- Add ampicillin or vancomycin for enterococcal coverage
- Do not rely on meropenem alone
Healthcare-associated infections requiring broad coverage:
- Use meropenem for gram-negatives AND add specific anti-enterococcal agent
Critical Pitfalls
- Do not assume carbapenem coverage includes enterococci - this is a common and dangerous misconception
- The FDA indication for E. faecalis in skin infections is based on limited data and should not be extrapolated to other infection types
- Meropenem has no activity against E. faecium, the more resistant enterococcal species 6
- Relying on meropenem monotherapy for serious enterococcal infections risks treatment failure
Bottom Line
While meropenem has an FDA indication that includes E. faecalis for skin infections, clinical guidelines do not recommend it as an anti-enterococcal agent. When enterococcal coverage is needed, use ampicillin, piperacillin-tazobactam, or vancomycin. If a patient is already receiving meropenem for other pathogens and enterococcal coverage becomes necessary, add a specific anti-enterococcal agent rather than relying on meropenem alone.